Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Non-invasive Auricular Vagus Nerve Stimulation (taVNS) on Postural Control and Autonomic Responses in Stroke

17 de julho de 2026 atualizado por: Riphah International University

Effects of Non-invasive Auricular Vagus Nerve Stimulation (taVNS) on Postural Control and Autonomic Responses in Stroke Patients

This randomized controlled trial is conducted to determine the effects of transcutaneous auricular Vagus nerve stimulation (taVNS) on postural control in stroke patients (e.g., improvements in balance, mobility, and functional stability) and to evaluate the effects of taVNS on autonomic nervous system responses in stroke patients (e.g., changes in heart rate variability, blood pressure variability, skin conductance, and temperature).

Visão geral do estudo

Descrição detalhada

Stroke remains one of the leading causes of long-term disability worldwide, impacting millions of individuals each year. Beyond motor and cognitive deficits, stroke survivors often experience significant impairments in postural control and autonomic nervous system (ANS) regulation, both of which are essential for functional independence and overall quality of life. Impaired balance increases the risk of falls, while autonomic dysfunction-manifesting as irregular heart rate variability (HRV), blood pressure variability (BPV), and abnormal skin conductance and temperature-can lead to complications affecting cardiovascular stability and daily functioning.

Traditional rehabilitation approaches primarily focus on physical therapy to improve movement and strength; however, interventions that target neuromodulation and autonomic regulation are still underutilized in post-stroke care. This gap opens the door for novel, non-invasive techniques that can enhance neural recovery and improve both motor control and autonomic function.

Transcutaneous auricular vagus nerve stimulation (taVNS) is a non-invasive method that stimulates the auricular branch of the vagus nerve through external electrodes placed on parts of the ear, typically the tragus or cymba conchae. The vagus nerve is a critical component of the parasympathetic nervous system and plays a key role in maintaining autonomic balance, inflammatory regulation, and neuroplasticity. By stimulating the vagus nerve, taVNS is believed to influence brain regions associated with motor control, cardiovascular regulation, and arousal-including the nucleus tractus solitarius (NTS), locus coeruleus, thalamus, and insula.

Recent studies have shown that taVNS may enhance post-stroke recovery by promoting cortical reorganization, reducing neuroinflammation, and improving neural connectivity. It has also been found to modulate HRV and BPV, reflecting improvements in autonomic nervous system activity, and may contribute to better cardiovascular health and stress resilience. This randomized controlled trial aims to explore the therapeutic potential of taVNS in improving postural control and autonomic responses in patients recovering from stroke. Participants will receive taVNS using clinically standardized stimulation parameters (e.g., 25 Hz frequency, 250 μs pulse width, up to 6 mA intensity) administered for 30 minutes daily over 4 weeks. Postural outcomes will be evaluated using validated tools such as the Berg Balance Scale (BBS), Postural Assessment Scale for Stroke Patients (PASS), and Fugl-Meyer Assessment for Lower Extremities (FMA-LE). Autonomic responses will be assessed through heart rate variability, blood pressure variability, skin conductance, and skin temperature monitoring.

This study is significant because it addresses an important gap in stroke rehabilitation: the lack of non-invasive, targeted interventions that simultaneously improve both balance and autonomic function. By evaluating the dual impact of taVNS on these domains, this research has the potential to inform future stroke rehabilitation protocols, contributing to more holistic, patient-centered care. If effective, taVNS may offer a low-cost, portable, and easily integrated adjunct to conventional therapy, especially in low-resource settings or for patients with limited access to specialized care. In summary, this study investigates whether taVNS can serve as an effective tool to support postural stability and autonomic regulation in stroke survivors ultimately aiming to enhance recovery outcomes, reduce fall risk, and improve quality of life.

Tipo de estudo

Intervencional

Inscrição (Estimado)

22

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Punjab Province
      • Islamabad, Punjab Province, Paquistão, 44000
        • Recrutamento
        • Railway General Hospital, Rawalpindi
        • Contato:
        • Subinvestigador:
          • Abrish Habib Abbasi, Phd* Rehab
        • Investigador principal:
          • Hajra Arshad, MS-NMPT*

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Sim

Descrição

Inclusion Criteria:

  • Age between 18 to 70years who are diagnosed with ischemic brain injury, intracerebral hemorrhage shown by magnetic resonance imaging, or computed tomography.
  • First occurrence of stroke characterized by a unilateral lesion, with an onset time (acute/ subacute) < 6 months
  • With balance impairment (BBS Score = 21-44);
  • no or mild spasticity on the lower-limb assessed by Modified Ashworth Scale (MAS ≤ 2);
  • sufficient cognition to follow the instructions provided by the therapists and the computer.

Exclusion Criteria:

  • Individuals exhibiting unstable vital signs, consciousness disorders, or an inability to cooperate with examination and treatment procedures
  • Those with a heart rate below 60 beats per minute, or with implantable devices such as pacemakers or cochlear implants.
  • Other medical or psychological conditions affecting participation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Balance Training
Participants in the control group will also undergo baseline assessments without intervention. During Weeks 1 and 2, they will participate in daily or scheduled 30-minute balance training sessions, consisting of 14 basic exercises such as sit-to-stand, tandem stance, and single-leg stance. These exercises are designed to improve static and dynamic balance, and are tailored to the individual's ability and safety level. In Weeks 3 and 4, the balance training progresses in difficulty. This includes increasing repetitions or duration, adding dual-task challenges (like cognitive tasks while balancing), and incorporating tools like foam pads or wobble boards to increase instability and challenge postural control. Each session remains 30 minutes in length and is supervised for safety and consistency.
Participants in the control group will also undergo baseline assessments without intervention. During Weeks 1 and 2, they will participate in daily or scheduled 30-minute balance training sessions, consisting of 14 basic exercises such as sit-to-stand, tandem stance, and single-leg stance. These exercises are designed to improve static and dynamic balance, and are tailored to the individual's ability and safety level. In Weeks 3 and 4, the balance training progresses in difficulty. This includes increasing repetitions or duration, adding dual-task challenges (like cognitive tasks while balancing), and incorporating tools like foam pads or wobble boards to increase instability and challenge postural control. Each session remains 30 minutes in length and is supervised for safety and consistency
Experimental: Vagus Nerve Stimulation combined with Balance Training
Participants in the experimental group will receive transcutaneous auricular vagus nerve stimulation (taVNS) administered according to standardized clinical protocols. No intervention is provided at baseline, aside from initial assessments. During Weeks 1 and 2, taVNS will be applied daily or as per a specified schedule. The stimulation parameters include: application at the auricular site (such as the tragus), with a frequency of 25 Hz, pulse width of 250 µs, and intensity adjusted to individual tolerance, not exceeding 6 mA. Each session will last for 30 minutes. The same taVNS protocol continues through Weeks 3 and 4. This group will not perform physical balance exercises during the taVNS phase, focusing solely on neuromodulation through vagus nerve stimulation.
Participants in the experimental group will receive transcutaneous auricular vagus nerve stimulation (taVNS) administered according to standardized clinical protocols. No intervention is provided at baseline, aside from initial assessments. During Weeks 1 and 2, taVNS will be applied daily or as per a specified schedule. The stimulation parameters include: application at the auricular site (such as the tragus), with a frequency of 25 Hz, pulse width of 250 µs, and intensity adjusted to individual tolerance, not exceeding 6 mA. Each session will last for 30 minutes. The same taVNS protocol continues through Weeks 3 and 4. This group will not perform physical balance exercises during the taVNS phase, focusing solely on neuromodulation through vagus nerve stimulation.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Berg Balance Scale (BBS)
Prazo: 4 Weeks

A clinical tool used to assess static and dynamic balance through 14 functional tasks. Tasks include sitting, standing, reaching, turning, and single-leg stance. It evaluates a person's ability to maintain balance during common daily activities and helps determine the risk of falls, especially in stroke patients and older adults.

Scoring: Each item is scored from 0 to 4 (maximum score: 56)

  • Low fall risk: 41-56
  • Moderate fall risk: 21-40
  • High fall risk: 0-20
4 Weeks
Timed Up and Go Test (TUG)
Prazo: 4 Weeks

A simple test used to assess mobility, balance, walking ability, and fall risk. The participant is timed while standing up from a chair, walking 3 meters, turning around, walking back, and sitting down.

Scoring: Time recorded in seconds

  • <10 sec: Normal mobility
  • 10-20 sec: Good mobility, mostly independent
  • >20 sec: Limited mobility, may require assistance
4 Weeks
Postural Assessment Scale for Stroke Patients (PASS)
Prazo: 4 Weeks

A stroke-specific tool used to assess postural control in lying, sitting, and standing positions. It includes 12 items that evaluate the ability to maintain or change postures.

Scoring: Each item scored 0-3 (Total score: 36) Higher scores indicate better postural control.

4 Weeks
Fugl-Meyer Assessment - Lower Extremity (FMA-LE)
Prazo: 4 Weeks

A quantitative measure to assess motor recovery of the lower extremities in post-stroke patients. Evaluates reflexes, movement, coordination, and joint function.

Scoring: Each item scored on a 3-point scale (0 = cannot perform, 2 = performs fully)

• Maximum score: 34 for lower extremity

4 Weeks
Heart Rate Variability (HRV)
Prazo: 4 Weeks

A measure of the variation in time between heartbeats, reflecting autonomic nervous system activity, especially parasympathetic function.

Scoring: Time-domain and frequency-domain indices (e.g., RMSSD, LF/HF ratio) Higher HRV = better autonomic flexibility.

4 Weeks
Blood Pressure Variability (BPV)
Prazo: 4 Weeks

Evaluates variations in blood pressure over time, indicating autonomic regulation and cardiovascular stability.

Scoring: Standard deviation (SD), coefficient of variation (CV), or spectral analysis

• Abnormal variability may reflect autonomic dysfunction

4 Weeks
Skin Conductance and Skin Temperature
Prazo: 4 Weeks

Measures sweat gland activity and peripheral temperature, indicating sympathetic nervous system activity.• Increased skin conductance = higher sympathetic arousal

• Changes in skin temperature may reflect vasoconstriction/dilation

4 Weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Hajra Arshad, MS-NMPT*, Riphah International Unversity

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

20 de maio de 2026

Conclusão Primária (Estimado)

20 de outubro de 2026

Conclusão do estudo (Estimado)

20 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

1 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

1 de junho de 2026

Primeira postagem (Real)

5 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de julho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de julho de 2026

Última verificação

1 de julho de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever